Derek Archila's Stock Ratings

Wells Fargo Analyst

Derek Archila is an analyst at Wells Fargo. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/31/2024

Overall Average Return

7.95%

Smart Score

59.8%

Overall Average Return Percentile

56th

Number of Ratings

109
Buy NowGet Alert
05/23/2024APLSBuy Now
Apellis Pharmaceuticals
$39.2522.29%$57 → $48MaintainsEqual-WeightGet Alert
05/15/2024ANNXBuy Now
Annexon
$5.0996.3%$12 → $10MaintainsOverweightGet Alert
05/09/2024CCCCBuy Now
C4 Therapeutics
$5.0159.68%$7 → $8MaintainsEqual-WeightGet Alert
05/09/2024ARVNBuy Now
Arvinas
$33.1481.05%$63 → $60MaintainsOverweightGet Alert
05/03/2024ZYMEBuy Now
Zymeworks
$8.4841.51%$14 → $12MaintainsOverweightGet Alert
05/03/2024ASNDBuy Now
Ascendis Pharma
$135.1093.93%$260 → $262MaintainsOverweightGet Alert
04/18/2024RYTMBuy Now
Rhythm Pharmaceuticals
$35.6845.74%$53 → $52MaintainsOverweightGet Alert
04/11/2024ANABBuy Now
AnaptysBio
$23.94133.92% → $56Initiates → OverweightGet Alert
04/01/2024ANNXBuy Now
Annexon
$5.09135.56%$12 → $12MaintainsOverweightGet Alert
03/27/2024ANNXBuy Now
Annexon
$5.09135.56%$11 → $12MaintainsOverweightGet Alert
03/22/2024CABABuy Now
Cabaletta Bio
$10.19243.47%$34 → $35MaintainsOverweightGet Alert
03/21/2024SLRNBuy Now
Acelyrin
$4.10217.17%$11 → $13MaintainsEqual-WeightGet Alert
03/15/2024ASNDBuy Now
Ascendis Pharma
$135.1092.45%$196 → $260MaintainsOverweightGet Alert
03/14/2024MORBuy Now
MorphoSys
$18.57-1.71%$17 → $18.25DowngradeOverweight → Equal-WeightGet Alert
03/12/2024ZYMEBuy Now
Zymeworks
$8.4865.09%$12 → $14MaintainsOverweightGet Alert
03/12/2024VTYXBuy Now
Ventyx Biosciences
$4.89227.2%$7 → $16UpgradeEqual-Weight → OverweightGet Alert
02/20/2024ARGXBuy Now
argenx
$371.0228.83%$472 → $478MaintainsOverweightGet Alert
02/16/2024NRIXBuy Now
Nurix Therapeutics
$15.7526.98%$23 → $20MaintainsOverweightGet Alert
02/05/2024MORBuy Now
MorphoSys
$18.57-8.45% → $17ReiteratesOverweight → OverweightGet Alert
12/21/2023ARGXBuy Now
argenx
$371.0226.68%$585 → $470MaintainsOverweightGet Alert
12/19/2023KYMRBuy Now
Kymera Therapeutics
$32.11-19.03% → $26DowngradeOverweight → Equal-WeightGet Alert
12/19/2023VTYXBuy Now
Ventyx Biosciences
$4.89-38.65%$8 → $3MaintainsEqual-WeightGet Alert
12/19/2023RYTMBuy Now
Rhythm Pharmaceuticals
$35.6848.54%$48 → $53MaintainsOverweightGet Alert
12/19/2023BPMCBuy Now
Blueprint Medicines
$105.568.94%$86 → $115MaintainsOverweightGet Alert
12/19/2023ASNDBuy Now
Ascendis Pharma
$135.1010.29%$137 → $149MaintainsOverweightGet Alert
12/19/2023ARVNBuy Now
Arvinas
$33.1490.1% → $63UpgradeEqual-Weight → OverweightGet Alert
12/15/2023MORBuy Now
MorphoSys
$18.57-8.45%$10 → $17MaintainsOverweightGet Alert
12/14/2023APLSBuy Now
Apellis Pharmaceuticals
$39.2537.58%$67 → $54DowngradeOverweight → Equal-WeightGet Alert
12/13/2023SLRNBuy Now
Acelyrin
$4.10168.38% → $11Initiates → Equal-WeightGet Alert
11/14/2023KZRBuy Now
Kezar Life Sciences
$0.70185.71%$4 → $2MaintainsEqual-WeightGet Alert

Recent Analyst Stock Rating News

Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
Analyst Ratings For Arvinas
Key Takeaways From Nurix Therapeutics Analyst Ratings
The Analyst Landscape: 7 Takes On AnaptysBio
Breaking Down argenx: 12 Analysts Share Their Views
Key Takeaways From C4 Therapeutics Analyst Ratings
Zymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Analyst Expectations For Rhythm Pharmaceuticals's Future
The Analyst Verdict: argenx In The Eyes Of 12 Experts
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free